Dosing Guidlines for Adults

Drug Detail for Adult Drugs


Methadone

Analgesics

Narcotics and Narcotic Antagonists


General Toxicity Notes
Excreted Unchanged %
Hepatic
Half-Life (NormalESRD) hours
13-58/No data
Plasma Protein Binding %
60-90
Volume of Distribution L/kg
3-6
Dose for Normal Renal Function
2.5-10 mg q6-8h
Second Dose
Adjustment for Renal Failure Method
D
Adjustment for Renal Failure GFR, mL/min >50 [Recommended Level]
100% [D]
Adjustment for Renal Failure GFR, mL/min 10-50 [Recommended Level]
100% [D]
Adjustment for Renal Failure GFR, mL/min <10 [Recommended Level]
50-75% [D]
Supplement for Dialysis [Recommendation Level]: IHD
IHD: None
Supplement for Dialysis [Recommendation Level]: PD
PD: None
Supplement for Dialysis [Recommendation Level]: CRRT
CRRT: Dose for GFR 10-50, titrate, [D]
References
Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci. 1995; 245: 114-24. [PMID: 7654787] / Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987; 41: 392-401. [PMID: 3829576] / Quinn DI, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet. 1997; 33: 344-400. [PMID: 9391747] / S&#246; we J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986; 11: 87-106. [PMID: 3514045]
Toxicity Notes